Upadacitinib represents an effective oral alternative to tocilizumab for reducing glucocorticoid burden, particularly in patients with relapsing GCA or in patients with GCA who have an increased risk of glucocorticoid-related toxicity, with less profound suppression of inflammatory markers than tocilizumab.
Wolfgang A. Schmidt (Wed,) studied this question.